Immunoassay Market

The global immunoassay market is projected to reach USD 44.49 billion by 2031 from USD 31.65 billion in 2026, growing at a CAGR of 7.0% during the forecast period. The immunoassay market is supported by the rising incidence of chronic and infectious diseases, growing demand for early and accurate diagnosis, and increasing use of immunoassays across oncology, infectious disease testing, blood screening, and other diagnostic applications. Increasing adoption of automated, point-of-care, and rapid immunoassay-based testing is further contributing to market expansion. In addition, growth in biotechnology and biopharmaceutical industries, increasing demand for drug, alcohol, and cannabis screening, supportive government initiatives, and expanding healthcare infrastructure in emerging economies are supporting demand for immunoassay technologies. Technological advancements, including improved diagnostics, condition-specific biomarkers, companion diagnostics, and microfluidics integration, are expected to create additional growth opportunities. However, stringent approval requirements, technical challenges associated with immunoassay kits, antibody design and quality issues, and a shortage of skilled professionals may constrain market growth.

The global immunoassay market is consolidated, featuring companies such as Abbott Laboratories (US), F. Hoffmann-La Roche (Switzerland), Siemens Healthineers (Germany), Thermo Fisher Scientific Inc. (US), Danaher Corporation (US), Revvity (US), Becton, Dickinson and Company (US), DiaSorin S.p.A. (Italy), Bio-Rad Laboratories (US), QuidelOrtho Corporation (US), bioMérieux (France), QIAGEN (Netherlands), Sysmex Corporation (Japan), Agilent Technologies (US), Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (China), Merck KGaA (Germany), Meridian Bioscience (US), Bio-Techne (US), Cellabs (Australia), Abnova Corporation (Taiwan), J. Mitra & Co. Pvt. Ltd. (India), Tosoh Corporation (Japan), Cell Sciences (US), Enzo Biochem (US), Creative Diagnostics (US), Boster Biological Technology (US), Elabscience (US), WAK-Chemie Medical (Germany), SeraCare (US), Epitope Diagnostics (US), Kamiya Biomedical Company (US), Gyros Protein Technologies (Sweden), Trivitron Healthcare (India), Maccura Biotechnology Co., Ltd. (China), and InBios International (US). These market players have implemented several strategies, including product launches, acquisitions, agreements, collaborations, and expansions, to strengthen their market positions.

To know about the assumptions considered for the study download the pdf brochure

Abbott Laboratories (US) 

Abbott Laboratories (US) has established a strong position in the global immunoassay market, supported by its broad diagnostics portfolio and established laboratory presence. The company’s Alinity i and ARCHITECT immunoassay systems offer high-throughput testing across applications such as infectious diseases, oncology, endocrinology, and cardiology. Abbott continues to strengthen its position by expanding assay menus, automation capabilities, and laboratory workflow solutions. Its extensive global presence and established diagnostic infrastructure further support the adoption of its immunoassay platforms across hospitals, clinical laboratories, and blood screening facilities.

F. Hoffmann-La Roche (Switzerland)

F. Hoffmann-La Roche Ltd. (Switzerland) has established a strong position in the global immunoassay market through its Roche Diagnostics business and extensive portfolio of immunoassay solutions. Its cobas e-series and cobas pro integrated systems support high-throughput testing across applications including infectious diseases, oncology, cardiology, endocrinology, and women’s health. Roche continues to strengthen its market position through investments in assay development, laboratory automation, system integration, and digital diagnostic solutions, supported by its broad global presence and established network serving clinical laboratories and healthcare providers.

Market Ranking

As of 2025, the global immunoassay market is highly consolidated, with Abbott Laboratories (US), F. Hoffmann-La Roche Ltd. (Switzerland), Siemens Healthineers AG (Germany), Danaher Corporation (US), and Bio-Rad Laboratories, Inc. (US) among the leading players. These companies compete through broad immunoassay portfolios, established diagnostic platforms, extensive assay menus, automation capabilities, global distribution networks, and strong laboratory customer bases. Abbott maintains a strong position through its Alinity and ARCHITECT systems, while Roche has an established presence through its cobas immunoassay platforms. Siemens Healthineers strengthens its portfolio with integrated, automation-focused solutions, including Atellica, while Danaher, through Beckman Coulter, offers high-throughput immunoassay analyzers and automation solutions. Bio-Rad strengthens its position through its specialized immunoassay and diagnostic testing portfolio.

These leading companies are focusing on automation, assay menu expansion, throughput, analytical performance, workflow integration, and digital laboratory solutions to strengthen their competitive positions. Increasing demand for high-throughput diagnostic testing, the growing burden of chronic and infectious diseases, and expansion of healthcare and laboratory infrastructure across emerging markets are supporting market opportunities. Companies are further strengthening their positions through new product and assay launches, technology enhancements, strategic collaborations, portfolio expansion, and expansion of distribution networks, particularly across Asia Pacific and Latin America.

Related Reports:

Immunoassay Market by Product (Reagents & Kits, Analyzers), Technology (ELISA, IFA, Western Blot), Specimen (Blood, Saliva), Application (Infectious Diseases, Endocrinology, Cardiology), End User (Hospital, Blood Bank) & Region – Global Forecast to 2031

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
[email protected]